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Abstract: Major depression contributes significantly to the global disability burden. Since the
first clinical study of deep brain stimulation (DBS), over 446 patients with depression have now
undergone this neuromodulation therapy, and 29 animal studies have investigated the efficacy
of subgenual cingulate DBS for depression. In this review, we aim to provide a comprehensive
overview of the progress of DBS of the subcallosal cingulate in humans and the medial prefrontal
cortex, its rodent homolog. For preclinical animal studies, we discuss the various antidepressant-like
behaviors induced by medial prefrontal cortex DBS and examine the possible mechanisms including
neuroplasticity-dependent/independent cellular and molecular changes. Interestingly, the response
rate of subcallosal cingulate Deep brain stimulation marks a milestone in the treatment of
depression. DBS achieved response and remission rates of 64–76% and 37–63%, respectively,
from clinical studies monitoring patients from 6–24 months. Although some studies showed
its stimulation efficacy was limited, it still holds great promise as a therapy for patients with
treatment-resistant depression. Overall, further research is still needed, including more credible
clinical research, preclinical mechanistic studies, precise selection of patients, and customized electrical
stimulation paradigms.
Keywords: deep brain stimulation; treatment-resistant depression; major depressive disorder;
subcallosal cingulate; medial prefrontal cortex
1. Introduction
Major depressive disorder (MDD) contributes significantly to the global disability burden and
social burden [1,2]. In the US from 2005 to 2010, the economic burden of patients with major depressive
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disorder increased by 21.5% to $210.5 billion [3]. The main symptoms of MDD include severe
sadness, anxiety, cognitive deterioration, and suicidal thoughts [4]. Although its etiology is uncertain,
genetic predisposition, developmental deficits, hormonal imbalance, and a stressful lifestyle may
increase the risk for MDD [5–10].
Prior to the discovery of antidepressant medication, surgical ablation was used to effectively
treat MDD in the US and Europe [11]. Pharmacological antidepressants first appeared in
the late 20th century and these first-generation drugs became the first line treatment for
depression [12]. However, newer generations of antidepressants were barely more effective than
first-generation tricyclic antidepressants [13] and this has led to the emergence of treatment resistance.
Treatment-resistant depression (TRD) is the failure to respond to the three different classes of treatment:
antidepressants, psychotherapy, or electroconvulsive therapy given at a sufficient dose and time [14,15].
Approximately 20% to 30% of patients are refractory to pharmacotherapy and nearly 60% respond
inadequately [16,17], which can result in worse clinical responses, leading to additional social
burdens [18]. As the pathogenesis of MDD involves multiple structures, a broad-acting safe therapy
needs to be developed [19,20].
With much progress in surgical techniques and advances in cardiac pacemakers,
electrical stimulation has matured to become an adjustable stimulatory regimen [21]. Deep brain
stimulation (DBS) is a procedure whereby deep brain structures are stimulated via precisely
implanted electrodes. It was first used to alleviate movement disorders in patients with Parkinson’s
disease [22]. With advances in our understanding of the limbic circuitry, the focus has shifted to the
antidepressant-like effects of DBS [23]. Some recent clinical studies have shown that DBS holds great
promise in treating patients with TRD, and mechanistic studies in animals are currently in progress.
The use of DBS as a treatment for TRD was first proposed in a study by Kruger et al. on the
differences in regional cerebral blood flow (rCBF) between remitted patients and bipolar depression
(BD) patients [24]. They observed that rCBF in Brodmann Area 25 (BA25) was higher in remitted and
BD patients compared to control patients and this was also seen in healthy patients with self-rated
high negative affect [25]. Furthermore, Kruger et al. noted that mood provocation did not change
the rCBF to this region in BD patients compared to MDD patients, indicating that dysfunction in the
region was specific to depression [24]. Mayberg et al., who are pioneers of DBS as a treatment for
depression, subsequently targeted BA25 after detecting metabolic abnormalities within the region
that were consistent with those found in patients with TRD [19]. This landmark paper led to further
developments in the application of DBS of this region as a treatment for depression.
Indeed, several research groups have used DBS to treat depression by targeting different brain
regions in the limbic system. Jimenez et al. applied DBS to the inferior thalamic peduncle,
whereas Schlaepfer et al. applied DBS in the nucleus accumbens core [26,27] and successfully
performed DBS on the medial forebrain bundle [28]. With rapid developments in DBS as a treatment
for TRD, research is now focusing on the subcallosal cingulate (SCC). This review aims to examine
and consolidate clinical and preclinical research on the use of DBS as a treatment for depression,
targeting the subcallosal cingulate in humans and the ventromedial prefrontal cortex, the anatomical
correlate in rodents.
2. Outline of the Review
The online PubMed database was searched for research articles in English using a Boolean
operation with keywords including “deep brain stimulation” AND “depression” AND “subcallosal
cingulate” OR “rodent” AND “medial prefrontal cortex”. Relevant articles cited in the reference lists
of the identified publications were also included. PubMed was utilized due to its extensive collection
of indexed peer-reviewed journals. This review highlights the development of DBS as a treatment
for TRD and discusses the findings and limitations of preclinical and clinical studies published in
the recent decade. The neuroplasticity-dependent and -independent aspects of the molecular and
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cellular changes due to DBS are also discussed. Lastly, some potential approaches that may improve
the precision, safety, and efficacy of DBS are proposed.
3. The Development of Deep Brain Stimulation as a Treatment for Depression
Deep brain stimulation involves the stereotactic implantation of thin electrodes in deep
brain structures that are used to deliver electrical stimulation generated by a subcutaneous pulse
generator [29,30]. Stimulation is generally applied at either a low/moderate frequency (5–90 Hz) or high
frequency (100–400 Hz). Since the inception of DBS, a number of studies have demonstrated that this
modality has the ability to treat pain, obsessive-compulsive disorder, and Parkinson’s disease [16,21,31].
Its efficacy has been verified in Parkinson’s disease patients, in which high frequency stimulation (HFS)
of specific brain region(s) in the basal ganglia was able to stop tremors [21,32]. The use of DBS has
been given FDA approval for the management of obsessive-compulsive disorder since 2007, but it is
only provided under a humanitarian device exemption [33,34].
The following sections summarize the clinical studies on deep brain stimulation in the subcallosal
cingulate for treating patients with treatment-resistant depression and preclinical studies of deep brain
stimulation in the medial prefrontal cortex (mPFC) of rodents.
4. Clinical and Preclinical Studies of SCC DBS for the Treatment of Depression
Clinical studies of depression utilize rating scales of depression that assess changes in depressive
symptoms in patients. Some scales are completed by the researcher such as the Hamilton Depression
Rating Scale (HDRS) and the Montgomery-Åsberg Depression Rating Scale (MADRS). These rating
scales should allow more consistent assessment between patients, but can lack consensus in their
interpretation among researchers, which could lead to misdiagnosis [35]. Another weakness of rating
scales conducted in this manner is that the accuracy of the results is dependent on the communication
skills of the patient, which might be hampered by the disease itself. Other scales are completed
by patients such as the Beck Anxiety Inventory (BAI), Beck Depression Inventory (BDI), and Quick
Inventory of Depressive Symptomatology (QIDS). These rating scales should allow for a more accurate
reporting of depressive symptoms, although the number and/or depth of questions may vary across
different tests.
4.1. Progress in the Development of SCC-DBS
Different papers have referred to the SCC and similar regions under different names, e.g.,
the subcallosal cingulate gyrus (SCG), the subgenual cingulate, as well as Brodmann areas.
Different historical names allow for different historical context. The subgenual cortex is used more
interchangeably with the term Brodmann Area 25, named after Korbinian Brodmann. The subgenual
cortex is located in the cingulate region as a narrow band in the caudal portion of the subcallosal
area adjacent to the paraterminal gyrus. By comparison, the SCG is comprised of Brodmann areas
25, 24, and 32 [36]; SCG circuits; and limbic structures. The SCG is pivotal in mood, learning, reward,
and memory [37] and has been implicated as an aberrant region in MDD. As the SCC can be effectively
targeted by antidepressants, this makes the SCG a potential target of DBS against TRD [38,39]. Tables 1
and 2 list 39 clinical studies on the treatment efficacy of SCC-DBS for TRD.
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Table 1. A list of clinical studies on deep brain stimulation of the human subcallosal cingulate.
Authors Main Inclusion Criteria No. of Patients Stimulation Target & DBSDesign Stimulation Parameters
Clinical
Evaluation Major Outcomes Adverse Effects
Sankar et al. 2020 [40]
TRD MDE;
Current MDE ≥ 12 months;
HRSD-17 score ≥ 20;
Non-responsive (NR) ≥ 4
antidepressant therapies;
















Left and average SCG volume
significantly higher in responders
compared to non-responders.
Right and average amygdala
volume significantly higher in
responders compared to
non-responders.
Left, right, and average thalamus
volume significantly higher in
responders compared to
non-responders.
Brain grey matter volume
significantly lower in responders
compared to non-responders.
Ratio of grey to white matter




Riva-Posse et al. (2019) [41]
TRD MDE;
Current MDE ≥ 12 months;
HRSD-17 score ≥ 20;
Non-responsive (NR) ≥ 4
antidepressant therapies;





Sessions: 6 min session of 3 min
stimulation ON and 3 min
stimulation OFF.
Number of sessions:
12 trials (one at each of the eight





















Autonomic changes with SCC-DBS
correspond to salient behavioral
responses.
Distant effects of SCC-DBS in the
midcingulate cortex.
Increase in heart rate was only seen
with left SCC-DBS.
No significant relationship with
skin conductance.
These findings aid in the optimal
selection of contacts and
parameters in SCC-DBS surgery.
N.A.
Eitan et al. (2018) [42]
Both sexes, 21–70 years;
Non-psychotic MDD;
First MDE onset before 45
years old with current MDE
≥ 12 months;
NR ≥ 4 antidepressant
therapies; MADRS ≥ 22;
GAF < 50; MMSE > 24;
No changes in current
antidepressant treatments ≥





Two groups: High- OR
low-frequency DBS for 12 months
















Four out of nine patients
responded ♦ at the end of DBS
(≥40% reduction in MADRS from
baseline).
The effect of DBS at 6–12 months




Non-responders crossed over after
first 6 months of DBS.
Severe
One patient overdosed on
medication (dothiepin and
valium).
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Table 1. Cont.
Authors Main Inclusion Criteria No. of Patients Stimulation Target & DBSDesign Stimulation Parameters
Clinical
Evaluation Major Outcomes Adverse Effects
Merkl et al. (2018) [43]
Diagnosed MDD and
disease lasted for >2 years;
HAMD-24 score ≥ 20;
ATHF Score ≥ 3;
TRD: NR ≥ 2 antidepressant
therapies;
Failed to respond to
antidepressants and ECT;
No changes in current
antidepressant treatments





Two groups: sham-DBS (delayed
onset) OR non-delayed onset
group for the first 8 weeks in a
blinded manner.















Three out of eight patients
responded ** after 6 months DBS;
three out of seven with the same
criteria after 12 months.
Two out of six responded ** at the
end of DBS, follow-up at 28 months.
Two out of six patients reached
remission  at the end of DBS,
follow-up at 28 months.
This study showed a delayed
response in patients; no significant
antidepressant effects between











Howell et al. (2018) [44]
Both sexes aged 18–70 years;
current MDE ≥ 12 months;
NR ≥ 4
antidepressant therapies;
HRSD-17 score ≥ 20;
GAF score ≤ 50.
6

















All of the subjects responded.
Left and right cingulum bundles as
well as forceps minor are the most
likely therapeutic targets.
Right cingulum bundle activation
beyond a threshold may
protract recovery.
Uncinate fasciculus and frontal
pole were activated to a lesser
extent, may not be necessary for
anti-depressive effect of SCC-DBS.
Time to a stable response (TSR) was
8–189 days, 1-year HDRS-17
was 2–11.
Field cable modeling was more
accurate than volume of activated
tissue at approximating
axonal activation.
Overstimulation of CB-DBS can be
detrimental to the recovery process.
N.A.
Waters et al. (2018) [45]
Both sexes aged 18–70 years;
current MDE ≥ 12 months;
NR ≥ 4
antidepressant therapies;
HRSD-17 score ≥ 20;



















Symptom severity scores decreased.
three out of four patients in
remission (HDRS-17 ≤ 7).
Test-retest reliability across four
repeated measures over 14 months
met or exceeded standards for valid
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Table 1. Cont.
Authors Main Inclusion Criteria No. of Patients Stimulation Target & DBSDesign Stimulation Parameters
Clinical
Evaluation Major Outcomes Adverse Effects
Smart et al. (2018) [46]
TRD patients enrolled from
two separate clinical trials
for Deep Brain Stimulation.
Trial 1
Both sexes aged 18–70 years;




Current episode duration of
at least 1 year,
Non-responsive (NR) ≥ 4
antidepressant therapies.
Trial 2
Both sexes aged 25–70 years;
Current depressive episode
of at least 2 years duration
OR a history of more than
four lifetime
depressive episodes,








Pulse width: 90 µs
Current: 6 mA









6–8 mA for St. Jude Medical







11 of 14 patients met the criteria for
DBS antidepressant response by
6 months.
Of the three 6 month
non-responders, one responded
after the 6 month study endpoint
but without a contact change
(Patient 2), one responded after a
contact switch in the left
hemisphere (Patient 7), and one
remained a non-responder
(Patient 6).
Mean baseline HDRS-17 of 23.8 and
SD of 2.8; HDRS-17 of 9.6 and SD of
4.5 at month 6; 19.9 weeks for stable
response with SD of 20 weeks.
Precision on the left may be more
important than precision on the
right, which is supported by
theta decreases.
N.A.
Choi et al. (2018) [47]
Both sexes aged 18–70 years;
current MDE ≥ 12 months;
NR ≥ 4
antidepressant therapies;
HRSD-17 score ≥ 20;




Patients went through SCC-DBS,














Significant differences in the
pathway activation changes over
time between remitters and
non-remitters.
Non-remitters had significantly
larger net changes in their pathway
activation connection in both the
near and long term relative to the
initial plan.
N.A.




MADRS Score ≥ 22.
7
Targets SCC followed by Ventral
Anterior Capsule, nucleus
accumbens (separately, unless
patient in remission, and later
combined, for
non-responding patients).
Study Design DBS was applied
sequentially for 3 months per






Remitters had higher regional
cerebral blood flow in the baseline
prefrontal cortex and subsequent
tests when compared to
non-remitters and non-responders.
Chronic DBS increased prefrontal
cortex regional cerebral blood flow.
Remitted patients had higher
prefrontal cerebral blood flow
at baseline.
N.A.
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Table 1. Cont.
Authors Main Inclusion Criteria No. of Patients Stimulation Target & DBSDesign Stimulation Parameters
Clinical
Evaluation Major Outcomes Adverse Effects
Holtzheimer et al. (2017) [15]
Both sexes aged 21–70 years;
Unipolar,
non-psychotic MDD
First MDE onset before
45 years old with current
MDE ≥ 12 months;
NR ≥ 4
antidepressant therapies,
MADRS Score > 22; GAF <
50; MMSE > 24;
No changes in current
antidepressant treatments ≥





DBS or sham stimulation 2 weeks
after implantation for 6 months in
randomized and
double-blind manner.
Two groups: DBS or sham
then both groups received
open-label stimulation for 6




















Insignificant difference in response
* between sham and DBS at the end
of the 6-month double-blind phase.
38 patients responded * and 20
remitted  after 6 month DBS.
In 2 years of open-label active DBS,
48% achieved antidepressant




Eight of 40 events reported
related to device or surgery:
six infections (in five
patients), one skin erosion
over the extension wires,
and one postoperative
seizure.
McInerney et al. (2017) [14]
Current MDE ≥ 12 months;




























Significant reduction in HRSD-17





11 patients responded ** and nine
were non-responders.
WCST Test results indicated that
the total errors were predictive of
responsiveness to DBS.
No significant deterioration in
cognition and psychomotor speed.
Improvements in verbal memory
and verbal fluency.
N.A.
Riva-Posse et al. (2018) [49]
Both sexes aged 18–70 years;
current MDE ≥ 12 months;
NR ≥ 4
antidepressant therapies;
HRSD-17 score ≥ 20;




DBS from 4 weeks after surgery
and lasted for 6 months,
open-label.
Stimulation contacts were
changed in non-responders and













Eight out of 11 responded ** and six
remitted  after 6 month DBS.
Nine responded ** and six remitted
 after 12 month DBS.
Two did not respond throughout
the study.
Tractography-based surgery



















One patient was a responder (81%
change in MADRS score).
Responder’s contacts were closer to
the Tractography-guided optimized
target (TOT), unlike the
non-responder.
N.A.
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Table 1. Cont.
Authors Main Inclusion Criteria No. of Patients Stimulation Target & DBSDesign Stimulation Parameters
Clinical
Evaluation Major Outcomes Adverse Effects
Accolla et al. (2016) [51]
MDD;
NR to treatments;
Currently in a depressive
episode as in DSM-IV Axis I
disorders;





Each homologous electrode pair
was activated separately on
5 consecutive days,
then antidepressant effects was
assessed 24 h later.
Open-label DBS for up to
24 months.














Four out of five patients did not
show sustained response ** to DBS
(also ≥50% reduction in DBI).
One patient responded ** to DBS of
the bilateral posterior gyrus rectus
instead of the intended target
(BA25).
N.A.
Richieri et al. (2016) [52]
Diagnosed MDD;


















Remitted (QIDS SR-16 3/48) at
1 month after DBS and maintained
at the end of DBS.
Seizure
Hilimire et al. (2015) [53]
Both sexes aged 18–70 years;
Current MDE ≥ 12 months,
Non-responsive (NR) ≥ 4
antidepressant therapies,
HRSD-17 score ≥ 20,




DBS for 6 months, open-label.
Behavioral testing and
electrophysiological recording (i)
before electrode implantation, (ii)
















Reduced proportion of negative
self-descriptive words compared to
baseline after 1 month and
6 month DBS.
Significant reduction in P1
amplitude compared to baseline
(for negative word self-description)
after 1 month and 6 month DBS,






Both sexes aged 18–70 years;
current MDE ≥ 12 months;
NR ≥ 4
antidepressant therapies;
HRSD-17 score ≥ 20;




Chronic DBS for 9 months on
average for clinical stabilization.
A PET scan was acquired
(i) during active stimulation and













Decreased metabolism in BA24,
BA6, caudate putamen after
48 h DBS.
This study suggests metabolic
changes spread after longer periods
of no stimulation.
No clinical changes were detected
according to HAMD-17.
N.A.
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Table 1. Cont.
Authors Main Inclusion Criteria No. of Patients Stimulation Target & DBSDesign Stimulation Parameters
Clinical
Evaluation Major Outcomes Adverse Effects
Puigdemont et al. (2015) [55]
Severe TRD;
Both sexes aged 18–70 years;
current MDE ≥ 12 months;
NR ≥ 4 antidepressant
therapies;
HRSD-17 score ≥ 20;





After stable clinical remission to
DBS, patients were allocated to
two groups, one with
(i) 3 month DBS-ON, then
(ii) 3 month sham stimulation
(ON-OFF arm) or OFF-ON arm














Active stimulation: four of five
patients were remitted patients.
Sham stimulation: Only two
patients remained in remission,
another two relapsed, and one
showed a progressive worsening
without reaching relapse criteria.
N.A.





min. stage IV of
Thase-Rush scale;
HDRS score ≥ 18.
First Episode MDD
(FE MDD) Group





DBS began at 48 h postoperative
and ended when each patient had
stabilized response for at least
three consecutive visits, tests
conducted before surgery, and




















FE MDD and TRD saw significant
improvements over time
in memory.
No significant difference was
observed in both groups on
executive functioning, language,
and processing speed.





Choi et al. (2015) [57]
Both sexes aged 18–70 years;
current MDE ≥ 12 months;
NR ≥ 4
antidepressant therapies;
HDRS-17 score ≥ 20;
GAF score ≤ 50.
9
Target SCC
Intraoperative Sessions: 6 min
session of 3 min stimulation ON,
and 3 min stimulation OFF.
Number of sessions:
12 trials (one at each of the






















Behavioral switch was apparent to
patients within the first minute of
the initiation of stimulation and
effects were sustained while
stimulation remained on.
Three common white matter
bundles were affected by
stimulation: (i) the uncinate
fasciculus, (ii) the forceps minor,
and (iii) the left cingulum
bundle.Seven of nine patients with
left hemispheric contact had a
response to treatment at 6 months.
Sun et al. (2015) [58]
NR ≥ 4 antidepressant
therapies,




Session: 100 min, w/15 min break
EEG recording sessions/day
Session 1: DBS On
Session 2: DBS Random (On/Off)














Suppression of gamma oscillations
by DBS during working memory
performance and the treatment
efficacy of DBS for TRD may be
associated with the improved
GABAergic neurotransmission,
previously shown to be deficient in
MDD.The present study also
suggests that modifying treatment
parameters to achieve suppression
of gamma oscillations and
increased theta-gamma coupling
may lead to optimized DBS efficacy
for TRD.
N.A.
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Table 1. Cont.
Authors Main Inclusion Criteria No. of Patients Stimulation Target & DBSDesign Stimulation Parameters
Clinical
Evaluation Major Outcomes Adverse Effects
Perez-Caballero et al.
(2014) [59]
18–70 years old with MDE;
Resistant to
pharmacological treatment
and at most, a partial
response to ECT;
HAMD-17 Score ≥ 18.
8
Target SCG
Study Design All patients
received chronic DBS within 48 h
after implantation.
Four patients took NSAIDs for up











At week 1 after surgery, all patients
without NSAID prescription
responded ** and two remitted ;
three patients with NSAID
responded **, and two remitted .
At week 4 after surgery, three
patients without NSAID remitted
; no patients with NSAID
responded **
N.A.
Merkl et al. (2013) [60]
MDD;
NR to treatments;
Currently in a depressive
episode as in DSM-IV Axis
I disorder;
HAMD-24 score of ≥ 20;
HDRS-24 score ≥ 24.
6
Target SCG
Study Design DBS on 11–19 days
after electrode implantation, 24 h
acute stimulation followed by
sham stimulation for each of the
three electrode pairs.





















HAMD-24, BDI, and MADRS
scores for acute DBS and
sham stimulation.
0/4 contact pair locations showed
significant BDI and
MADRS improvements.
Contact pair 3/7 for Patient 4 saw a
77% reduction in HAMD-24 score
and 62% reduction of MADRS score.
Reduced HDRS-24, BDI, and
MADRS scores at the end of
chronic stimulation.
Two out of six remissions  at the










Ramasubbu et al. (2013) [61]
Aged between 20–60 years;
Diagnosed MDD;










Open-label continuous DBS for 6
months after optimization period.

















four patients showed maximal
response at longer pulse widths;
three patients experienced a 50%
reduction in HAMD-17 score.
Longer pulse widths were
correlated to short-term
improvement. Longer pulse width
also induced insomnia, confusion,
and drowsiness; improved by
turning off stimulation.
Chronic stimulation: two patients
responded ** at the end of
open-label DBS, with longer
pulse width.
Electrode targets suggested to be
individualized, as opposed to
standard as in movement disorders,
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Table 1. Cont.
Authors Main Inclusion Criteria No. of Patients Stimulation Target & DBSDesign Stimulation Parameters
Clinical
Evaluation Major Outcomes Adverse Effects
Torres et al. (2013) [62]
Type I bipolar depression;





DBS from 15 days after






















Broadway et al. (2012) [63]
Both sexes aged 18–70 years;
current MDE ≥ 12 months;
NR ≥ 4
antidepressant therapies;
HRSD-17 score ≥ 20;



















Reduced HDRS-17 scores between
baseline and the end of DBS among
all patients.
Six patients had significantly
reduced HRSD-17 scores ** at the
end of DBS.
Increased frontal theta cordance
between baseline and week 4 in
responders correlated with their
decreased depressive state at later
time points.
N.A.
Hamani et al. (2012) [64]
TRD;























Before relapse: SCC-DBS reduced




therapeutic effect of DBS;
HAMD-17 score lowered from 22 to
16 (after 2 weeks), to 8 (after 2
months) and to 9 (after 4 months).
N.A.
Holtzheimer et al. (2012) [65]
Both sexes aged 18–70 years;
current MDE ≥ 12 months;
NR ≥ 4
antidepressant therapies;
HRSD-17 score ≥ 20;




Intraoperative testing of electrode
location for 12 or 17 patients.
Stimulation:
(i) 4 weeks of sham stimulation,
followed by
(ii) 24 weeks of open label DBS
for 24 weeks, followed by
(iii) single-blind discontinuation
for 1 week and open label
















11 patients responded ** and seven
further remitted  after 2 year DBS.
Efficacy was similar for patients
with MDD and those with BP.
A modest sham stimulation effect
was found, likely due to a decrease
in depression after the surgical
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Table 1. Cont.
Authors Main Inclusion Criteria No. of Patients Stimulation Target & DBSDesign Stimulation Parameters
Clinical
Evaluation Major Outcomes Adverse Effects
Lozano et al. (2012) [66]
Both sexes aged 30–60 years;
First MDE before 35 years;


















Improved global functioning and
less severe depression.








Puigdemont et al. (2012) [67]
18–70 years old with MDE;
Resistant to
pharmacological treatment
and at most, a partial
response to ECT;




feedback was provided during
surgery for electrode placement.
DBS began at 48 h postoperative
and ended when each patient had
stabilized their response for at














Seven patients responded ** and
three remitted  after
6 month DBS.
Five patients responded ** and four
remitted  after 12 month DBS.
Three out of four remitted patients
after 12 month DBS had remitted





Kennedy et al. (2011) [18]
Current MDE ≥ 12 months;






















64.3% patients responded ** at the
last follow-up visit.
35% patients remitted  at the last
follow-up visit.
Scores at the last visit tended
towards maintenance of




(All determined to be
unrelated to DBS).










Positioning was aided by
intraoperative feedback.
Bilateral DBS was conducted for
12 months.
Followed by unilateral-left, then













Patient’s condition plateaued after
6 month bilateral DBS.
Left unilateral DBS led to rapid
worsening in mood.
Right unilateral DBS reversed the
symptoms and the patient made
significant improvements over
bilateral stimulation. Patient
remitted at 18 months.
Orthostatic hypotension.
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Table 1. Cont.
Authors Main Inclusion Criteria No. of Patients Stimulation Target & DBSDesign Stimulation Parameters
Clinical





Had suicidal ideation in
current MDE;




HAM-D score was 25
1
Target SCC
Study Design Positioning of
electrodes was aided by
intraoperative feedback














HAMD-17 score lowered to 9 at the
end of DBS follow-up.
Sustained antidepressant response
up to 2 years after surgery
N.A.
Hamani et al. (2009) [70]
Diagnosed MDD;







Study Design DBS began at 2













11 responded ** at the end of 6
month DBS follow-up.
Electrodes in responders were
positioned ventrally relative to the
landmarks of the medial
prefrontal lobe.
N.A.
Puigdemont et al. (2009) [71]












Study Design DBS for 4 months,
then switched off because of
relapse and administered ECT for
3 weeks
Resumed DBS until 12 months












Sustained response without the
need of ECT before relapse.
Maintained remission in DBS after
ECT until the end of follow-up.
N.A.
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Table 1. Cont.
Authors Main Inclusion Criteria No. of Patients Stimulation Target & DBSDesign Stimulation Parameters
Clinical
Evaluation Major Outcomes Adverse Effects
Lozano et al. (2008) [72]
Current MDE ≥ 12 months;





Study Design Blinded-DBS in
between and after surgery,

















Mean HRSD-17 score lower than
baseline at all time points.
12 patients responded ** to DBS, 7
remitted  after 6 month DBS.
11 patients responded ** to DBS, 7
were nearly remitted or remitted 
after 12 month DBS.
Eight responses maintained from 6
month to 12 month DBS.
PET Scans: decreases in orbital,
medial prefrontal cortex, and
insula. Increases in lateral
prefrontal cortex, parietal, anterior,
and posterior cingulate by 6
months; increases in metabolic









McNeely et al. (2008) [73]
Current MDE ≥ 12 months,
HRSD-17 score ≥ 20,
Non-responsive (NR) ≥ 4
antidepressant therapies,






















6 months: four responded at the
end of DBS **
General Neuropsychological
Performance:
Manual Motor Skills: Improved for
dominant and non-dominant hand
by 12 months.
Verbal learning: Restored
impairments in two patients at the
end of 12 months.
No significant correlations between
change in mood and
neuropsychological function at 6
and 12 months.
N.A.
Neimat et al. (2008) [74]
Family history of severe
MDD.







Study Design Started DBS on the
day after electrode implantation












HAMD-17 score decreased from 19
before surgery to 8 at 6 months
after DBS.
Sustained remission until the end
of DBS study (scored 7)
N.A.
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Table 1. Cont.
Authors Main Inclusion Criteria No. of Patients Stimulation Target & DBSDesign Stimulation Parameters
Clinical
Evaluation Major Outcomes Adverse Effects
Mayberg et al. (2005) [19]
Current MDE ≥ 12 months,
HRSD-17 score ≥ 20,





1–5 min on-off stimulation in
acute DBS for
5 days postoperative.
Chronic DBS for 6 months after
pulse generator was implanted
























Acute effects: Sudden feeling
of calmness
Chronic effects: five patients
responded ** after 2 month DBS.
Response maintained in four
patients at the end of 6 month DBS.
Three patients achieved remission







* ≥40% reduction in MADRS and average GAF in months 4–6 not worse than baseline; ** ≥50% reduction in HRSD-17 (HAMD-17) score from baseline; *** ≥40% reduction in HRSD-17
score from baseline; ♦ ≥40% reduction in MADRS compared to mean baseline;  HAMD-24 scores or MADRS scores ≤ 10 after DBS;  HRSD score < 8.  HRSD score ≤ 8; Abbreviations:
ATHF = Anti-depressant Treatment History Form, BA25 = Brodmann Area 25, BDI/-II = Beck Depression Inventory/-II, CGI, PGI, CANTAB = Clinician and Patient Global Impression of
Severity and Improvement (CGI; PGI) and cognitive function (CANTAB); CVLT = California verbal learning test, DBS = deep brain stimulation, DWI = Diffusion-weighted imaging, ECG
= electrocardiogram, ECT = electroconvulsive therapy, EDA = electrodermal activity, EEG = electroencephalography, GAF = Global assessment function, HAM-A = Hamilton Anxiety
Rating Scale, HRSD-17/HDRS-17 = Hamilton Rating Scale for Depression/ Hamilton Depression Rating Scale, (f)MRI = (functional) magnetic resonance imaging; MADRS/MARDS =
Montgomery-Åsberg Depression Rating Scale, MAOI = monoamine oxidase inhibitors, MDD = major depressive disorder, MDE = major depressive episodes, MMSE = Mini-Mental State
Examination, NSAID = non-steroidal anti-inflammatory drug, NR = non-responsive, PET = positron emission tomography, QIDS/-SR = Quick Inventory of Depressive Symptomatology/-self
report, Q-LES-Q = Quality of Life and Satisfaction Questionnaire, SCC = subcallosal cingulate, SCG = subcallosal cingulate gyrus, SCR = skin conductance response, QOL = Quality of Life
Enjoyment and Satisfaction Questionnaire, TRD = treatment-resistant depression, WSAS = Work and Social Adjustment Scale.
J. Clin. Med. 2020, 9, 3260 16 of 49
Table 2. Summary of response and remission rates from clinical studies.
Authors

















Sankar et al. 2020 [40] NA NA NA NA NA NA NA NA
Riva Posse et al. (2019) [41] NA NA NA NA NA NA NA NA
Eitan et al. (2018) [42] NA NA NA NA 44.4 NA NA NA
Merkl et al. (2018) [43] 37.5 12.5 43 14.2 33 33 33 NA
Howell et al. (2018) [44] - - 33.3 66.7 - - - -
Waters et al. (2018) [45] NA NA NA NA NA NA NA NA
Smart et al. (2018) [46] - - 78.5 - - - - -
Choi et al. (2018) [47] NA NA NA NA NA NA NA NA
Conen et al. (2018) [48] - - 28.6 42.9 - - - -















McInerney et al. (2017) [14] - - 55 - - - - -
Riva-Posse et al. (2018) [49] 72.7 54.5 81.8 54.5 - - - -
Tsolaki et al. 2017 [50] 50 - - - - - - -
Accolla et al. (2016) [51] - - - - 79 20 - -




- - - - - - -
Hilimire et al. (2015) [53] NA NA NA NA NA NA NA NA
Martin-Blanco et al. (2015) [54] NA NA NA NA NA NA NA NA
Puigdemont et al. (2015) [55] - 80 - - - - - -
Serra-Blasco et al. (2015) [56] - - - - 75 (F.E.)87 (TRD) - - -
Choi et al. 2015 [57] NA NA NA NA NA NA NA NA
Sun et al. 2015 [58] NA NA NA NA NA NA NA NA
Perez-Caballero et al.
(2014) [59] 50 - - - - - - -
Merkl et al. (2013) [60] - - - 30 - - - -
Ramasubbu et al. (2013) [61] 50 - - - - - - -

















Broadway et al. (2012) [63] 50 - - - - - - -







- - - - -
Holtzheimer et al. (2012) [65] 18 41 36 36 58 92 - -
Lozano et al. (2012) [66] 57 - 48 - 62 - - -
Puigdemont et al. (2012) [67] 37.5 37.5 87.5 37.5 62.5 50 - -
Kennedy et al. (2011) [18] - - 62.5 - 46.2 - 75 -


































Hamani et al. (2009) [70] - - 55 - - - - -








- - - - -
Lozano et al. (2008) [72] 35 10 60 35 - - - -
McNeely et al. (2008) [73] 66 NA - - - - - -









Mayberg et al. (2005) [19] 66 50 - - - - - -
Average 63.8% 43.9% 66.5% 36.5% 69.3% 42.4% 76% 62.5%
Range 18–100 10–100 28.6–100 12–66.7 33–100 17–92 33–100 12–100
The first evidence-based clinical study on SCC-DBS was published by Mayberg et al. in 2005 [19].
Among six patients with an average of 5.6 years of major depressive episode (MDE), four responded to
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the treatment, but three remitted or nearly remitted during the stimulation, even without changing
medications. The authors found that the metabolic activity in the SCC normalized from a hyperactive
state and was accompanied by reduced local blood flow as detected by Positron Emission Tomography
(PET) [19]. In a study from 2003 to 2006 by Lozano et al. on chronic DBS in 20 patients with an average
of 6.9 years of current MDE, 11 patients responded, but seven remitted [72], which was similar to the
response and remission rates of Mayberg et al. In a 3.5-year follow-up study, the response rate was
consistent across time points, but the remission rate increased from 18.8% to 42.9% at the last visit [18].
Both studies reported changes in structures distal to SCC after DBS, which explains the persistent
response throughout the DBS treatments [18,72].
In a case report by Neimat et al., a 55-year-old female TRD patient who relapsed after a subgenual
cingulotomy, achieved sustained remission for up to 30 months with SCC-DBS treatment [74]. In a case
reported by Guinjoan et al. in 2010, a 60-year-old male TRD patient responded to unilateral SCC-DBS
in the right hemisphere, but unilateral stimulation in the left hemisphere worsened his mood. This is
in line with the asymmetrical response to antidepressants in the SCC region. However, the authors
noted a further study was needed with more patients to validate the effects of unilateral stimulation on
mood enhancement [68].
Similarly, in a preliminary study in 2012 by Puigdemont et al. on eight patients with an average
of 6.3 years of current MDE, they found that five patients responded at the end of the 12-month DBS,
but three out of four final remitters remitted after 3 months of DBS [67]. Their cognitive functions
were not exacerbated and their memory functions were actually improved in cognitive assessments in
2015 [56]. Concurrently, a clinical study conducted in three different medical centers also reported
similar efficacies of SCC-DBS, suggesting that DBS has reliable stimulation effects. Among 21 patients
with an average of 5 years of current MDE, 13 responded to the treatment and the rest performed
better than at baseline by the end of the study, although one patient committing suicide by medication
overdose [66].
4.2. Remission Rates
Some previous studies reported higher initial response and/or remission rates compared to
more recent studies [19,67,72]. In the study by Perez-Caballero et al., they suggested that electrode
insertion-induced inflammation could affect response and remission rates. Four of the eight recruited
patients took non-steroidal anti-inflammatory drugs (NSAIDs), which resulted in a diminished
antidepressant response toward DBS, whereas the other four not taking NSAIDs gradually responded
and remitted. The authors also analyzed the role of inflammation in the early DBS response in rats [59],
which is discussed in a later section of this review. A later study in 2015 by Puigdemont et al. reported
that remission was maintained in four out of five remitted patients in the 3-month active stimulation
group, whereas only two patients remitted in the sham stimulation group. They concluded that
continuous active stimulation was important in maintaining the therapeutic effect [55]. This was
supported by an earlier case of a 27-year-old patient on DBS for 2 years whose symptoms worsened
due to battery depletion, but improved again upon battery replacement [69].
Table 2 reflects the different response and remission rates, at 6-month intervals, across the duration
of the studies in Table 1. This reporting allows for a cursory longitudinal tracking in understanding
how response and remission may change with time. Among the reviewed studies on DBS, the response
rate ranged from 18% to 87.5% and remission rate ranged from 10% to 92% (excluding all case studies)
across the different time points (see Table 2), which were comparable to earlier clinical studies [19,72].
However, large-scale controlled trials are needed to further validate the efficacy of DBS in patients
with TRD. Some predictive markers discovered in these studies could facilitate the selection of more
responsive patients and increase the safety of DBS. A noteworthy study by Holtzheimer and Mayberg
demonstrated some changes in the response and remission rates with DBS [69]. The authors noted that
several months after a response and/or remission in their depressive symptoms, worsening of symptoms
was temporarily observed at 16 weeks. They attributed the temporary worsening of symptoms to
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the difficulty of some patients reintegrating into society. In an earlier study by Lozano et al. in 2008,
they also observed a similar occurrence at 4 months. These findings highlight the complexity of treating
neuropsychiatric diseases, as the recovery periods are not always consistent and can be affected by
different factors.
4.3. Significant Challenges in the Development of SCC-DBS
A larger study that aimed to recruit 201 patients was conducted by Holtzheimer et al. in 2017 to
further validate the therapeutic effects of DBS [15]. A futility analysis conducted after 90 patients had
been recruited showed no significant differences between the DBS and sham groups, leading to the early
termination of the study. During a 6-month double-blind trial, no significant differences were found in
the response of the DBS group compared to the sham group. However, among 77 patients that received
subsequent open-label DBS for up to 2 years, 38 responded and 20 remitted. Holtzheimer et al. offered
several explanations for the observed result. First, the patients selected for the study had an average
current episode duration of around 12 years, whereas most studies recruited patients with an average
current depressive episode of about 3–5 years. Holtzheimer also posited the possibility of suboptimal
contact during the first 12 months, further affecting the results. This landmark paper was initially
thought to be the death knell for DBS as a treatment for TRD. However, a summit of key academics
within the field determined that DBS protocols required further modification and patient recruitment
needed refining to better assess the therapeutic effects of DBS for TRD [75]. Considering that multiple
other studies showed the efficacy and effectiveness of DBS for TRD, the conference considered several
possibilities for the discrepancies in the findings, some conclusions were that DBS was initiated too
early before optimal targeting was secured, a lack of specificity and standardization in the improvement
of symptoms, high placebo effects typically seen in the treatment of psychiatric disorders, and study
design. The heterogeneity of the symptoms of the disease was also emphasized, which suggested that
different circuitry might be involved in different individuals. The key conclusions from the summit
included that patient selection should be better and more refined, study designs should be either fast
to fail or fast to succeed, registries should be established for better subject tracking, and longitudinal
data should be collected. The paper stressed that the complexities of the disease were real and better
experimental designs were needed to truly reflect the effects of DBS as a treatment for TRD for a better
response and remission rate and to allow the elucidation of the mechanistic role of DBS.
4.4. Adverse Effects
The safety of SCC-DBS was subsequently assessed following the initial results of the efficacy of
DBS in treating TRD. In 2008, McNeely et al. conducted a trial on six patients with an average of
5.6 years of current MDE. They found that mood was significantly improved during the 1-year DBS
treatment without serious cognitive deterioration [73]. Moreines et al. found that DBS treatment in
both unipolar and bipolar TRD patients with at least 2 years of current MDE improved executive
functions and stabilized their memory [76]. Similarly, SCC-DBS for 6 months followed by depression
treatment in patients with MDD, who had increased negative emotional processing and/or reduced
positive emotions, resulted in reduced negative emotional bias [53]. Martín-Blanco et al. reported that
a 52-year-old female had a seizure after 5 weeks of DBS. As severe MDD may predispose patients to
seizures, the authors recommended that patients should be evaluated for seizures before administering
DBS and parameters might need to be adjusted to within safe ranges [52]. In a study in 2017 by
McInerney et al. on 20 unipolar TRD patients with an average of 6.9 years of MDE, they reported
that 11 patients responded at the end of the 12-month DBS without further deterioration of cognitive
functions. They also found a correlation between verbal fluency and mood improvement, which could
be predictive of the DBS response [14]. The side effects reported in this review range from mild
symptoms, such as headaches, dizziness and gastrointestinal irritation [43,66], to more severe effects
including suicidal ideation and device malfunction [15,67]. This reporting should not discourage the
development of therapies. Indeed, many treatments including serotonin-selective reuptake inhibitors
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have severe side effects, including increased fractures and suicidal ideations [77,78]. In the study of
therapies, it is important to report these side effects and to note that these therapies are administered
by a professional, whose role is to detect and modulate the therapies accordingly.
4.5. Stimulation Parameters
Several studies have attempted to optimize the parameters of DBS for treating mood disorders.
As previously mentioned, Eitan et al. reported that high-frequency stimulation (HFS) was more
effective at lowering MADRS scores compared with low frequency stimulation [42]. Indeed, the most
commonly used stimulation frequency was in the high frequency range of 130–135 Hz, although some
studies have tested frequencies between 5 and 185 Hz [19,61] (see Table 1). The pulse width used in
DBS also varied greatly across studies. In a study by Ramasubbu et al., they found that a long pulse
width of 180–270 µs was effective [61]. However, this study also reported that DBS with a long pulse
width caused patients to experience stimulation-induced insomnia, anxiety, confusion, and drowsiness.
Previous studies by Lozano et al. and Holtzheimer et al. demonstrated that shorter pulse widths
of 30–60 µs led to clinical improvements in depression symptoms without these side effects [66,72].
Indeed, Ramasubbu et al. suggested that longer pulse widths with lower amplitudes and shorter pulse
widths with higher amplitudes could produce comparable therapeutic benefits. The amplitude of the
stimulating current used in DBS to elicit a therapeutic response also tended to vary across studies.
The amplitude is the first parameter to be adjusted when patients do not respond to the treatment.
Among 38 clinical studies, the overall current range was 2–8 mA and voltage range was 2.5–10.5 V.
The variability in the amplitude underscores the personalized nature of DBS, which requires specific
adjustments to achieve individual therapeutic effects.
4.6. Electrode Implantation
Several clinical DBS studies have also tried to improve the accuracy of electrode implantation
in order to precisely target regions of interest. The pioneering work by Mayberg et al. used PET
scans of pathological glucose metabolism to guide the electrode implantation. Riva-Posse et al. used
individualized tractography maps based on a group connectome blueprint of past responders to
DBS to identify optimal target regions for electrode implantation [49]. Riva-Posse et al. used a
four-bundle white matter blueprint, which resulted in good clinical outcomes in eight out of 11 patients,
which suggests that the use of this method could improve the precision of implantation. Similarly,
Tsolaki et al. investigated the use of FMRIB Software Library (FSL) probabilistic tractography in
SCC-DBS [50]. Several studies have used other methods to try to specify the optimal stimulation points.
Choi et al. investigated the best contact positions that elicited the best response during intraoperative
testing [57]. They used diffusion-directed magnetic resonance imaging and patient-specific tractography
maps to guide the implantation. They also used fiber tract probabilistic tractography to determine
the putative fiber tract activation in patients, which was used to guide the electrode implantation for
the best response, rather than the salient response. Contacts in the left hemisphere were found to
produce the best consistent intraoperative response to DBS in seven out of nine patients at 6 months.
Smart et al. validated this result in their study using local field potentials following unilateral
HFS-DBS [46]. They found that left-sided stimulation evoked broadband effects, compared with right
sided stimulation, which evoked only beta and gamma bands. Additionally, a decrease in theta bands
was consistently accompanied by behavioral improvements. They concluded that the precision of
electrodes in the left-hemisphere was more important and instructive than in the right hemisphere.
In contrast, Guinjoan et al. and Howell et al. found that right hemisphere targets were critical for
behavioral improvements [44,68]. Guinjoan et al. showed that right unilateral DBS could reverse and
remit a patient’s worsening mood induced by left unilateral DBS. Howell et al. showed that right
cingulate bundle activation beyond a threshold could protract the recovery. Further research is needed
to elucidate the differences in these studies.
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4.7. Other Responses to DBS
With regard to other potential responses to DBS, recent studies have attempted to characterize
non-behavioral evoked responses. Conen et al. identified higher rCBF in patients at baseline and
during DBS therapy compared to non-remitters and non-responders [48]. Riva-Posse et al. observed
autonomic changes in responders undergoing DBS [41]. In a study by Smart et al., assessing the
efficacy of DBS, they found consistent changes in left theta local field potentials, which could provide
another consistent parameter to monitor. Based on this finding, they proceeded to adjust the contacts
for one non-responder, who was able to achieve a response by the end of the study. In a study by
Sankar et al. on responders and non-responders who had previously undergone SCG-DBS, they found
that both groups had significant volume differences in the left and average SCG; in the right and
average amygdala; and in the left, right, and average thalamus (Sankar et al. 2020). Additionally,
non-responders had significantly greater grey matter volume compared to responders and a greater
grey to white matter ratio. This important information provides yet more criteria for assessing if a
patient might respond to DBS. Expanding the breadth of data obtained during clinical trials has the
potential to advise clinicians on the efficacy of DBS, and to help predict non-responders and adjust the
stimulation parameters. This will improve patient welfare and allows for a more accurate examination
of the mechanisms of DBS in improving depressive-like symptoms.
Furthermore, it would be prudent to use preclinical results to advise clinical cases. In a previous
preclinical study, Hamani et al. reported that DBS supplemented with tranylcypromine increased the
antidepressant-like response in animals by 20%–30% compared to either treatment alone. They later
reported on a patient who relapsed after 4 years of remission following DBS treatment [64]. Based on
their previous work, they administered tranylcypromine before the DBS treatment, which allowed the
patient to enter remission again.
5. Preclinical Studies of Electrical Stimulation in the Medial Prefrontal Cortex in Rodents
Following the success of a number of preliminary clinical studies, several preclinical studies were
conducted to investigate the antidepressant-like effects of DBS [79]. The mPFC in rats is widely regarded
to be homologous to the SCC in humans. The mPFC together with the amygdala, hippocampus,
and hypothalamus controls the stress response, autonomic functions, and cognition in rats [80–83].
Using PET imaging, glucose metabolism was observed to normalize in the mPFC from a hyperactive
state following DBS, which was similarly observed in the SCC after 1 h of DBS [84]. However,
the homology between subdivisions of mPFC and SCC is still under debate. The vmPFC can be
further subdivided into the infralimbic (IL) and prelimbic (PrL) regions. Although there are overlaps,
the IL and PrL innervate different regions to different extents, including the lateral hypothalamus,
dorsal raphe nucleus, and amygdala, among efferent regions [85–87]. The PrL has been shown to
innervate to important limbic regions associated with SCC projections [87]. Meanwhile, the infralimbic
cortex (IL) is believed to be structurally homologous based on comparisons involving tractography
analysis [88–90]. Some assert that the whole ventromedial prefrontal cortex (vmPFC) is homologous to
the SCC [91,92]. Others assert that the vmPFC is functionally distinct from the dorsal medial prefrontal
cortex [70,91]. Nevertheless, the vmPFC is generally regarded as homologous to BA25, although a
thorough understanding of specific correlations remains to be seen. Table 3 lists 29 preclinical studies
on the effects of vmPFC-DBS on animal behaviors.
5.1. vmPFC Stimulation
Hamani et al. published the first preclinical study of vmPFC-DBS in rats in 2010. They used
the forced swim test (FST), which models “helplessness” in animals including anxiolytic-like
and anti-anhedonic-like behavior. They found DBS reduced the immobility score in FST,
indicating antidepressant-like effects. The authors attributed the behavioral changes to serotonergic
function in the dorsal raphe nucleus (DRN) as lesions in this structure abolished the behavioral effects
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in FST [91]. Another animal study in 2012 found the optimal stimulation frequency and amplitude
of vmPFC-DBS was 130 Hz and 200 µA that produced anti-anhedonic-like effects and produced
a charge density similar to DBS in humans [93]. They found a lesion in the DRN abolished the
higher sucrose consumption due to DBS, even with a normal hippocampal brain-derived neurotrophic
factor (BDNF) profile. They postulated that an interaction between BDNF and neurochemical
substances potentiated the antidepressant-like response [92]. The anti-anhedonic-like effects of DBS
were also supported in studies by Rea et al. and Edemann-Callesen et al. They conducted an
intracranial, self-stimulation paradigm in Flinders sensitive line and Flinders resistant line rats to assess
reward-seeking behaviors, which demonstrated that the anti-anhedonic-like effect of vmPFC-DBS
was independent of the dopaminergic reward system [94,95]. Bruchim-Samuel et al. reported
that modulation of the ventral tegmental area could prolong the behavioral changes. They found
that intermittent acute patterned stimulation administered to the ventral tegmental area of Flinders
sensitive line rats resulted in antidepressant-like and anti-anhedonic-like behaviors [96]. Strikingly,
a study by Bregman et al. in 2018 found that the antidepressant-like effect of DBS was serotonin
transporter-independent. This could be of benefit to some patients with a mutated serotonin
transporter-promoter gene (5-HTTLPR), which underlies the poor response to conventional selective
serotonin re-uptake inhibitors that target serotonin transporters [97].
Beside changes in neurochemical and neurotrophin profiles, neuroplasticity changes induced
by DBS have also been investigated. For instance, Bambico et al. reported increased hippocampal
neurogenesis and BDNF levels after vmPFC-DBS, which led to anti-anhedonic-like behaviors, but was
not sufficient for an overall antidepressant-like effect [98]. Correspondingly, Liu et al. found a correlation
between vmPFC-HFS and hippocampal neurogenesis and improvements in short- and long-term
memory in middle-aged rats. This suggests that DBS has therapeutic potential in age-dependent
memory deficits [99].
5.2. Other Brain Targets
As preclinical studies have progressed, several brain targets of DBS have been established.
Hamani et al. in 2014 demonstrated that DBS in the nucleus accumbens induced a similar
antidepressant-like effect to DBS in the vmPFC, even though the stimulations modulated different
circuits. This may contribute to more customized stimulation targeting based on the patient’s
symptoms [100]. Bregman et al. reported that the HFS of the medial forebrain bundle induced
antidepressant-like behaviors in the FST [101]. Interestingly, this antidepressant effect was not
mediated by increases in either serotonin or dopamine release in the nucleus accumbens. Lim et al. in
2015 emphasized that only HFS of the vmPFC led to anti-anhedonic-like effects and these pronounced
antidepressant-like effects were induced by modulating the activity of serotonergic neurons in the
DRN [102]. However, the authors did not investigate the effects of different stimulation parameters
on depressive-like behaviors in various DBS targets. The study by Etiévant et al. supported the
modulation of DRN by DBS and added that glial integrity was a prerequisite to the antidepressant-like
outcome [103]. In another study, mice subjected to chronic social defeat stress were administered
7 days of 5-h vmPFC-DBS, which resulted in increased social interactive behavior accompanied
by DRN modulation [104]. Interestingly, a recent study demonstrated that the potentiation of the
anxiolytic response to vmPFC stimulation was associated with exposure to an enriched environment.
This indicates that an enriched living environment can facilitate the beneficial effects of DBS
intervention [105]. Creed et al. conducted DBS on the entopeduncular and the subthalamic nuclei
to compare antidepressant-like effects [106]. Chronic Subthalamic nucleus DBS was reported to
impair performance in the learned helplessness task, with no significant effects in anxiety tests.
These results were associated with decreased hippocampal BDNF and TrkB mRNA. Interestingly,
entopeduncular nucleus DBS did not increase depressive-like behavior in the learned helplessness
task, indicating a superior target over the subthalamic nucleus for the treatment of depressive-like
behaviors. Meng et al. reported reductions in depressive-like behaviors in animals stimulated in
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the lateral habenula; this observation was associated with elevations in dopamine, norepinephrine,
and serotonin in both blood serum and in the hippocampus [107].
5.3. vmPFC-Linked Modulation of Other Structures
Other structures have been found to be modulated by vmPFC-DBS. For example, Lim et al. reported
that activation of the medial subthalamic nucleus contributed to antidepressant-like behavior [108].
In a rat model of post-traumatic stress disorder, IL-DBS reduced firing in the basolateral amygdala,
which attenuated fear and produced a slight anxiolytic-like effect [109]. A recent study showed that DBS
resulted in elevated spontaneous firing of noradrenergic locus coeruleus neurons and strengthened the
coherence between the prefrontal cortex and locus coeruleus. The latter was protective against stress
and was responsible for the antidepressant-like effect seen in FST [110]. On the other hand, Insel et al.
reported that there was reduced communication between IL and ventral hippocampus in rats after
10 days of 8-h IL-DBS and such coherence was higher in depressed subjects [111]. Jiménez-Sánchez et al.
in 2016 reported two studies on acute IL-DBS in naive and olfactory bulbectomized rat models.
In naive animals, IL-DBS induced antidepressant-like behaviors and increased prefrontal glutamate
efflux, which activated the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR)
to modulate DRN output [81]. In olfactory bulbectomized rats, similar changes were noted
in the prefrontal serotonergic and glutamatergic output with the activation of AMPAR and
antidepressant-like behaviors [33].
5.4. Synergism with Other Treatments
Antidepressant-like effects in different DBS paradigms are leading to some advancements in
the field. One such investigation by Laver et al. in 2014 examined the use of augmentation agents
such as buspirone, risperidone, and pindolol to enhance DBS efficacy. However, these agents did
not increase the antidepressant response of the rats receiving DBS treatment, when compared to
those co-administered monoamine oxidase inhibitors in previous studies [64,112]. It is possible that a
response may become evident in clinical trials. Perez-Caballero et al. in 2014 reported an interesting
early response to stimulation, in which sham-treated rats had reduced immobility and increased
swimming in FST at weeks 1 and 2, but not at week 6 post treatment. They reasoned that this was
caused by insertion-induced inflammation as pretreatment by indomethacin reduced the expression of
pro-inflammatory mediators (TNF-α, COX1, COX2) and reversed the antidepressant-like behaviors
in sham-treated animals [59]. Rummel et al. in 2016 reported that chronic continuous HFS did not
have more benefits than chronic intermittent stimulation in treatment-resistant rats with congenitally
learned helplessness [113].
5.5. Other Biological Parameters Modulated
Similar to the research direction of clinical studies, preclinical studies have also attempted
to characterize other biological parameters of DBS, including more precise electrode implantation.
Lehto et al. characterized real-time fMRI responses in the brain following DBS, and found strong
connectivity between the vmPFC and amygdala, which validated vmPFC as a target region [114].
Perez-Cabalerro et al. used PET scans to study the immediate effects of electrode implantation.
They found that metabolism was decreased locally (vmPFC), but was increased in ventral regions,
including dorsal and ventral hippocampus, piriform and insular cortex, nucleus accumbens,
ventral tegmental area, ventral pallidum, hypothalamus, and the preoptic area [115]. This was
in agreement with other studies on the effect of DBS on depressive-like behavior, but it is noteworthy
to see these effects simply via electrode insertion.
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Table 3. A list of preclinical studies on deep brain stimulation of the medial prefrontal cortex in rodents.
Authors Target Animal Animal Models & DBS Design Stimulation Parameters Behavioral Tests Outcomes
Jia et al. (2019) [116] vmPFC Sprague-Dawley rats,
male.
CUS animal model.










Pulse Width: 0.2 µs
Sucrose preference test

















Papp et al. (2019) [117] vmPFC




Two, 2-h DBS sessions were conducted,
one on the preceding evening and the
other on the following morning before




Pulse width: 90 µs
Sucrose intake test


















antagonist, but not in
D2-administered
CMS animals. VFX
also did not rescue
groups administered
with D3 antagonist.
Bhaskar et al. (2018) [105] vmPFC Wistar rats,male.
Naïve animal model.










efficacy of HFS on
reduced escape
latency time in the
Naïve animal model.
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Table 3. Cont.
Authors Target Animal Animal Models & DBS Design Stimulation Parameters Behavioral Tests Outcomes
Elevated plus maze
HFS with an enriched
environment reduced






Bregman et al. (2018) [97] vmPFC
SERT homozygous knockout
and wildtype mice, male.
Serotonin transporter (SERT) knockout
model.















counts than sham and
wild-type mice.
Lehto et al. (2018) [114] IL Sprague-Dawley rats,male.
Naïve animal model.
All stimulation paradigms consisted of
three blocks of 60 s of rest and 18 s of
stimulation, ending with an additional
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Amplitude: 1.4–1.7 mA distributed


















to the position of the
electrode.
Papp et al. (2018) [118] vmPFC Wistar rats,
male.
CMS animal model.
Two, 2-h DBS sessions were conducted,
one on the previous evening and one the
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Volle et al. (2018) [119] vmPFC Sprague-Dawley rats,male.
Stimulation was delivered 1 week after
surgery for either
(i) a single day (acute stimulation;
8 h/day) or
(ii) 12 days (chronic stimulation daily for
8 h/day) using a portable stimulator
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Table 3. Cont.
Authors Target Animal Animal Models & DBS Design Stimulation Parameters Behavioral Tests Outcomes
Reznikov et al. (2017) [109] IL Sprague-Dawley rats,
male.
Posttraumatic stress disorder animal
model.
3-day fear conditioning
DBS from 1 week after extinction recall
to the end of experiment, 8 h/day, or 2 h
before and 4 h after behavioral tests.
Frequency: 130 Hz
Amplitude: 100 µA
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Rummel et al. (2016) [113] vmPFC






Chronic intermittent DBS 1 week after
surgery in Flinders sensitive line rats, 30
min each morning and extra 30-min
stimulation on afternoons before the day
of behavioral test.
Experiment 2
Chronic continuous DBS 1 week after
surgery for 16 days.
Experiment 3
Chronic intermittent DBS in congenitally
learned helpless rats, procedures
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rats but not cLH rats.
Sucrose intake test No significantdifference observed.
Novelty exploration test No significantdifference observed.
Bambico et al. (2015) [98] vmPFC Fisher rats,Male.
CUS animal model
CUS for ~4 weeks until anhedonia
inferred by SPI scores, then
performed implantation
DBS for 3 weeks after implantation, 8 h
per day, 7 days per week
Frequency: 130 Hz
Amplitude: 100 µA
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Authors Target Animal Animal Models & DBS Design Stimulation Parameters Behavioral Tests Outcomes
Open field test No significantdifference observed.
Elevated plus maze test


































Etiévant et al. (2015) [103] IL Sprague-Dawley rats, male.
Naïve animal model.
DBS for 4 h after forced swim pre-test
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CUS for 3 weeks, each stressor lasted for
10–14 h
DBS for 15 min before home-cage
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Reduced immobility
duration in HFS-CUS.
Lim et al. (2015) [108] PrL Sprague-Dawley rats, male.
Naïve animal model.
DBS for 15 min before and during
sucrose intake test (same for forced
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Sucrose intake test Increased sucroseconsumption.
Forced swim test Reduced immobility.
Liu et al. (2015) [99] vmPFC
Sprague-Dawley rats, male.
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Novel object
recognition test












object, as well as the
durations.
J. Clin. Med. 2020, 9, 3260 32 of 49
Table 3. Cont.
Authors Target Animal Animal Models & DBS Design Stimulation Parameters Behavioral Tests Outcomes
Morris water maze
Shorter latency to
reach platform on day
1 and 2 in chronic HFS
compared to sham.
More time spent in
the target quadrant




Hamani et al. (2014) [100] vmPFC Sprague-Dawley rats, male.
Naïve animal model.
DBS for 4 h after FST on day 1, 2 h before
swimming on day 2
DBS 1 week after forced swim test, 4 h















Laver et al. (2014) [112] vmPFC Sprague-Dawley rats, male.
Naïve animal model.
Serotonin reuptake inhibitors/vehicle
were injected i.p. 1 h and 5 h after forced
swim test on day 1 and 1 h before forced
swim test on day 2.
DBS for 4 h on day 1 of forced swim















Open field test No significantdifference observed





Electrode implantation after week 4 of
CUS, then CUS resumed.
DBS for 4 h after forced swim pre-test
and 2 h before forced swim test.
Some animals received pre-treatment
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Authors Target Animal Animal Models & DBS Design Stimulation Parameters Behavioral Tests Outcomes
Open field test No significantdifference.
Rea et al. (2014) [95] vmPFC
Flinders sensitive line rats,
male.
Flinders resistant line rats,
male.
(Control)
DBS for 30 min each morning for 2
weeks.
Extra DBS for 30 min in the afternoon













in both groups of rats.
Veerakumar et al.
(2014) [104] vmPFC C57BL/6 mice, male.
Chronic social defeat stress
animal model.



















Hamani et al. (2012) [92] vmPFC Wistar rats,male.
CUS animal model.
















Hamani et al. (2010) [93] vmPFC, IL, PrL Sprague-Dawley rats,male
Naïve animal model
DBS for 4 h after FST on day 1, 2 h before
swimming on day 2
Frequency: 20 Hz/130 Hz
Amplitude: 100/200/300/400 µA
Pulse Width: 90 µs
Forced swim test
Parameters of 130 Hz,
90 µs, 200 µA reduced
immobility the most
in vmPFC-DBS, also
at 100 µA and 300 µA.
PrL stimulation at 130
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Authors Target Animal Animal Models & DBS Design Stimulation Parameters Behavioral Tests Outcomes
Hamani et al. (2010) [91] vmPFC Sprague-Dawley rats,
male
Naïve animal model, with serotonergic
depletion, or norepinephrine lesion.
DBS for Forced Swim Test
Day 1: 4 h after forced swim test
Day 2: 2 h before forced swim test
DBS for open field test,
novelty suppressed feeding test,
and learned helplessness.
Pre-test Day 1: 4 h
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Authors Target Animal Animal Models & DBS Design Stimulation Parameters Behavioral Tests Outcomes
Animals predisposed to helplessness.
DBS for 2 h before baseline assessment,
2 h before footshock at 2 days after
baseline test, and DBS for 2 h before












Abbreviations: Cg, cingulate cortex; CUS, chronic unpredictable stress; EPM, elevated plus maze; FST, forced swim test; HFS, high-frequency stimulation; IL, infralimbic cortex; LFS,
low-frequency stimulation; MWM, Morris water maze test; NORT, novel object recognition test; NSFT, novelty-suppressed feeding test; OBX, olfactory bulbectomy; OFT, open field test;
PrL, prelimbic cortex; SD, Sprague-Dawley; SPI, sucrose preference index; vmPFC, ventromedial prefrontal cortex.
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Preclinical studies have progressed from studying the behavioral effects of DBS to understanding
the accompanying cellular and molecular changes, be they local or distal nodes in the neurocircuitry.
However, issues concerning the rodent homologs of SCC and the effect of stimulation in the subdivisions
of vmPFC have yet to be resolved and are discussed in the later part of the review.
6. Potential Mechanisms of Stimulation-Induced Antidepressant-Like Activities
Several preclinical studies reported that DBS modulates neuronal activities in different brain
regions, leading to antidepressant-like behaviors (Figure 1A). The network-wide cellular and molecular
changes caused by vmPFC-DBS can be classified into neuroplasticity-dependent and -independent
changes (Figure 1B). Neuroplasticity-dependent effects included neurogenesis, increased synaptic
plasticity, enhanced neurotrophin signaling, and potential activation of glial cell-mediated changes,
whereas neuroplasticity-independent effects included changes in serotonergic (5-HT) and glutamatergic
neurotransmission patterns, either locally or in distal structures. Other changes outside the scope of
this review might also be relevant.
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Figure 1. (A) Changes in loc an distal neuronal activity after electrical stimulation of the
ventromedial prefrontal cortex. (B) Neuroplasticity-dependent and -independent changes in
different structures following vmPFC-DBS. Abbreviations: AH, anterior hypothalamus; AMPAR,
α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor; BDNF, brain-derived neurotrophic
factor; BLA, basolateral amygdaloid nucleus; Cg1,2, cingulate gyrus area 1, 2; CM, centromedial thalamic
nucleus; DG, dentate gyrus; DMH, dorsomedial hypothalamus; DRD, dorsal raphe nucleus, dorsal part;
DRVL, dorsal raphe nucleus, ventrolateral part; IntMC, interposed cerebellar nucleus, magnocelluar
part; LA, lateral amygdaloid nucleus; LEnt, lateral entorhinal cortex; LHb, lateral habenula; MD,
mediodorsal thalamic nucleus; mPFC, medial prefrontal cortex; OrbF, orbitofrontal cortex; PaMP,
paraventricular hypothalamic nucleus, medial parvicellular; Pir, piriform cortex; PrL, prelimbic cortex;
TeA, temporal association area; and 5-HT, serotonin.
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Neuroplasticity-Dependent Effects of Electrical Stimulation
(i) Neurogenesis is a Long-Term Cellular Change Brought About by Electrical Stimulation
Post-mortem studies, pharmacological analyses, and electroconvulsive therapy reports have
led to the neurogenic hypothesis of the pathogenesis of depression, whereby atrophy and apoptosis
of hippocampal neurons correlated with depression and neurogenesis induce antidepressant-like
effects [120,121]. As CA1 and subiculum in the hippocampus project substantially to the
IL and the latter feeds back to the hippocampus via the relay nucleus reuniens in the
thalamus [102,122], vmPFC-DBS induces a corollary of hippocampal neuromodulation that may
mediate the antidepressant-like outcome. Etiévant et al. found that there was increased neurogenesis
in the dentate gyrus of the dorsal and ventral hippocampus in rodents after 1-h IL-DBS, as detected
by positive BrdU cells, and this was accompanied by reduced immobility in FST [103]. Similarly,
Liu et al. reported proliferation of neuronal progenitors after chronic vmPFC-DBS, as demonstrated by
increased positive BrdU and Dcx cell counts, as well as upregulated expressions of genes related to
neurogenesis (NeuN, Syn, Dcx, Nes) and neuronal differentiation and protective functions (Angpt2,
S100a4). These results were correlated with enhanced memory function, which may serve as another
indication of vmPFC-DBS [99]. Bambico et al. confirmed that new cells with mature neuronal phenotype
were found in the hippocampus after vmPFC-DBS, as detected by BrdU and NeuN co-expression.
They also reported that temozolomide-induced reduction of these cells led to a longer latency to feed in
a novelty-suppressed feeding test, but did not significantly change immobility in FST. This prompted
the authors to further examine the anxiolytic-like and anti-anhedonic-like effects of vmPFC-DBS.
In contrast, Winter et al. showed that 1 h of vmPFC-DBS with established DBS parameters in rodents
did not increase the percentage of BrdU and Dcx double-stained cells in the dentate gyrus compared
to the control [123]. Although research on the interaction between neurogenesis and substrates
such as serotonin is ongoing, BDNF may be required to exert this antidepressant-like effect [98].
Neurogenesis is a widely investigated mechanism of DBS and these results indicate positive effects in
the hippocampal region.
(ii) Synaptic Plasticity is Altered More Rapidly by Electrical Stimulation than by Neurogenesis
Disruption in synaptic functions and signaling are implicated in the pathophysiology of MDD,
considering their importance in neurotransmission and ultimately, in cell survival [20]. Chronic stress,
a risk factor of MDD, was shown to cause retraction of dendrites in the medial prefrontal cortex [124]
and CA3 of the hippocampus [125] in rodents. In the latter, the long-term potentiation (LTP) of synapses
was compromised, affecting long-term memory formation [126]. Regarding the changes in synaptic
plasticity caused by vmPFC-DBS, Liu et al. reported denser secondary dendritic spines in the dentate
gyrus, as demonstrated by upregulated Syn expression correlated with Nes and Dcx. The authors also
reported a slight (1.2 fold) increase in hippocampal BDNF gene expression, a regulator of synaptic
plasticity [99]. More recently, Bezchlibnyk et al. found that 1 h of IL-DBS resulted in longer dendritic
length and branch points localized in the basal and apical regions of hippocampal CA1 neurons,
respectively. These results indicated that the acute stimulation stressed the indispensable connections
between the hippocampus and vmPFC, which may have implications in MDD and its treatment [127].
Chakravarty et al. found that 5 days of 6-h vmPFC-DBS daily in 9-week-old C57Bl/6 mice
resulted in a larger hippocampal volume and increased hippocampal synaptic density, as indicated
by upregulated synaptophysin expression, a presynaptic marker [128]. Similarly, Veerakumar et al.
found that chronic vmPFC-DBS in transgenic mice increased dendrite length and complexity of the
5-HT DRN neurons and upregulated the expression of postsynaptic markers synaptophysin and
PSD-95 [104]. Moreover, Etiévant et al. reported synaptogenesis in the DRN, as indicated by higher
expressions of PSD-95 and synapsin. This may explain the prolonged DRN neuronal activation during
and after vmPFC-DBS, leading to an antidepressant-like effect [103]. According to earlier reviews,
dendritic spines can respond swiftly and provide surfaces for synapse formation [126,129]. Given the
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more dynamic properties of synapses compared to neurogenesis, synaptic plasticity may serve as
an early indicator of vmPFC-DBS efficacy. More preclinical studies characterizing the dynamics of
synaptic plasticity under vmPFC-DBS are anticipated.
(iii) Neurotrophin Signaling Underlies the Antidepressant-Like Effect of Electrical Stimulation
The neurotrophin BDNF is important in synaptic regulation, neuronal survival, and differentiation
of new neuron terminals in the adult brain [130–132]. Preclinical studies reported that depressive-like
rats subjected to chronic unpredictable stress [92,98] or olfactory bulbectomy [33] had lower BDNF
levels, whereas DBS increased BDNF levels, thus preventing the development of depressive-like
behaviors. Extracellularly, pro-BDNF is cleaved by tissue plasminogen activator/plasmin to form
mature BDNF. The high-affinity tropomyosin-related kinase B (TrkB) receptor is activated by BDNF [133],
leading to downstream phosphorylation of kinases, including protein kinase B (Akt) and extracellular
signal-regulated kinases (ERK), which are important mediators of anti-apoptosis and proliferation,
respectively [134]. Moreover, BDNF-TrkB triggers Serine 133 phosphorylation of transcription factor
cAMP response element binding (CREB), leading to the formation of the dimer. The phosphorylated
CREB dimer forms a larger transcriptional complex and alters multiple gene expressions including
BDNF itself [135]. Encouragingly, Jiménez-Sánchez et al. showed that IL-DBS administered to olfactory
bulbectomized rats activated these signaling pathways, as demonstrated by lowered Akt/pAkt,
ERK/pERK, and CREB/pCREB ratios during 1 h of stimulation that increased again after stopping the
stimulation, which was similar to the expression pattern of BDNF [33]. Further molecular studies are
needed to characterize the action of vmPFC-DBS toward different targets in this signaling cascade.
(iv) Potential Involvement of Glial Cells in Mediating the Outcome of Electrical Stimulation
Glial cells may be involved in the pathogenesis of depression, as revealed by post-mortem studies
of MDD patients, which found lower densities in the prefrontal cortex and amygdala, but increased
levels in the hippocampal hilus [136–138]. The latter may be activated as a result of neuronal injury
and decreasing neuronal populations [139,140]. Glial cells metabolically support neurons and regulate
glutamate synthesis and thus, regulate synaptic plasticity. They may be modulated by DBS to
potentiate the therapeutic effects [136]. This mechanism was supported in a study by Etiévant et al.,
which found that glial lesion by L-alpha-aminoadipic acid injection diminished antidepressant-like
behaviors, hippocampal neurogenesis, and LTP induced by IL-DBS [103]. These findings led to the
hypothesis that the neuronal-glial relationship is a determinant of the antidepressant-like efficacy
of DBS, but this requires further study. Perez-Caballero et al. also studied the effects of electrode
implantation and analgesic supplements [115]. They found that implantation with non-NSAID
analgesic treatments, like tramadol and morphine, did not ameliorate the anti-depressant effects
of the electrode implantation. This observation was accompanied by an increase in glial marker
GFAP-positive cells. This finding suggests that the supplementation of non-NSAIDs postoperatively
could improve the comfort of patients.
Neuroplasticity-Independent Effects of Electrical Stimulation
Besides modulating neuroplasticity-dependent mechanisms, DBS may manipulate some
neuroplasticity-independent pathways to induce antidepressant-like effects. In a chronic mild
stress model, depressive-like behaviors developed without significant deterioration of hippocampal
neurogenesis or neuronal survival [141]. There are two likely inter-related neurotransmission systems
that potentiate DBS efficacy, namely serotonergic and glutamatergic systems.
(i) An Alternative Action of the Serotonergic System by Electrical Stimulation
Results from preclinical studies have established an important role of the vmPFC-DRN axis and
downstream 5-HT neurotransmission in the treatment of depression. Hamani et al. first reported that
5-HT neurotransmission was augmented by DBS, as shown by a four-fold increase in hippocampal
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5-HT after 1 h of vmPFC-DBS [91]. The authors also suggested a relationship between the integral 5-HT
system and DBS efficacy, as 5-HT depletion induced by DRN lesions with 5,7-dihydroxytryptamine
injection diminished the antidepressant-like effects of vmPFC-DBS [91,92]. Similarly, a study by
Perez-Caballero et al. showed that the administration of para-chlorophenylalanine ester impeded 5-HT
biosynthesis and diminished the antidepressant-like behaviors in early DBS among IL sham-treated
animals [59]. Interestingly, Volle et al. showed that DBS and fluoxetine could rescue the 5-HT system
via different mechanisms [119]. Both treatments increased the amount of 5-HT at the end of the chronic
treatments, but chronic fluoxetine treatment was associated with decreased expression of 5-HT1A in
the prefrontal cortex and the hippocampus, whereas chronic DBS increased 5-HT1B expression in the
prefrontal cortex, globus pallidus, substantia nigra, and raphe nuclei.
A study by Veerakumar et al. in a transgenic mouse model of chronic social defeat stress
revealed normalization of 5-HT neuron excitability in DRN after vmPFC-DBS [104]. Moreover,
Jiménez-Sánchez et al. found increased prefrontal 5-HT efflux after 1 h of IL-DBS in olfactory
bulbectomized rats [33] and in naive rats [81]. Etiévant et al. also found spontaneous DRN 5-HT
neuron activity increased with IL-DBS [103]. Strikingly, an electrophysiological study performed by
Srejic et al. showed that IL-DBS decreased the firing rate of DRN neurons, including serotonergic
subtypes via the activation of GABAergic interneurons and possibly by the inhibition of excitatory
glutamatergic neurons that modulate the firing of 5-HT [142]. Hence, the positive response to DBS could
be enhanced by more selective targeting of the neuronal population by pharmacological adjuncts or
coupling with optogenetic techniques. A study by Bregman et al. in 2018 using a serotonin transporter
knockout mouse model found that DBS increased hippocampal 5-HT concentration, despite mice
responding poorly to fluoxetine, a conventional selective serotonin reuptake inhibitor that acts on
serotonin transporter [97]. These findings revealed a novel antidepressant-like activity of DBS involving
the 5-HT system primarily in the DRN [79].
(ii) Glutamatergic Neurotransmission is a Promising Target of Electrical Stimulation
Jiménez-Sánchez et al. showed that there was enhanced prefrontal glutamatergic efflux together
with changes in the local 5-HT profile [33,81]. The administration of AMPAR agonist and antagonist and
subsequent FST showed that the increased glutamate led to antidepressant-like behaviors in animals [81].
The authors also found increased synthesis of the GluA1 subunit of AMPAR and postulated that their
postsynaptic membrane insertion may explain the antidepressant-like outcome after 1 h of IL-DBS [33].
The activated glutamate output from the medial prefrontal cortex and frontal cortex enhanced 5-HT
neuronal firing in the DRN [143], resulting in the antidepressant-like effect. However, Etiévant et al.
argued that their activation was attributed to increased synaptogenesis in the DRN as previously
described [103]. Nevertheless, Lim et al. hypothesized that a glutamatergic projection from the
vmPFC to the medial subthalamic nucleus [144] may account for the antidepressant-like effects of
vmPFC-DBS, as seen by increased c-Fos-immunoreactive cells in the medial subthalamic nucleus,
increased sucrose consumption, and reduced immobility duration in FST [108]. With the emergence of
glutamate-targeting pharmacotherapy [81], the ability to modulate glutamatergic transmission of DBS
would add to the therapeutic novelty.
7. Concerns and Limitations of the Electrical Stimulation Studies
The small sample sizes in several clinical studies might compromise the credibility of the DBS
efficacy, even in studies with similar recruited DBS subjects or consistent outcomes [18,56]. Most of
the clinical studies were open-label, which means the responses could be prone to the placebo effect,
despite the early response characterized by Perez-Caballero [59]. Efficacy of DBS treatment could be
overestimated, unless countered by long stimulation, randomization, and blinding [18,145], such as
double-blinded and sham-controlled studies [55]. A major criterion in preclinical studies is that they
should mimic clinical studies. As it is unfeasible to stimulate animals for 24 h a day as in clinical
designs [128], the scheduling of the stimulations and behavioral assessments will thus be relevant
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to the validity of the outcomes. Stimulation during behavioral tests will be most similar to clinical
studies, but this may interfere with the physiological functions of the animals [79]. Besides, DBS is
normally carried out in animals for relatively short periods and the effects might not correlate well
with chronic stimulation [33]. Some preclinical studies were conducted in naive animal models
and would not be compatible with clinical trials as TRD patients will be recruited exclusively in
clinical settings [33,93]. Moreover, carry-over effects and lesion effects may interfere with the results
in both settings. Carry-over effects refer to behavioral or neurochemical changes after DBS ceases.
This needs to be counteracted by a washout period to allow the subjects to resume their baseline
physiological states before the next stimulation [79]. Lesion effects occur where responses are observed
after electrode implantation [19,60,72]. This needs to be differentiated from true responses observed in
preclinical studies by sham-treatment [67], otherwise, the therapeutic effect will be over-estimated.
Generally speaking, care must be taken in the design of experiments and data analysis of preclinical
studies to increase their translational value to clinical studies.
8. Prospective Approaches to Enhance Deep Brain Stimulation Safety and Efficacy
Clinical response to SCC-DBS and various predictors can facilitate precise patient selection and
customize the stimulation targets, thereby yielding maximal therapeutic outcomes with minimal
adverse effects. For example, a lower baseline frontal theta cordance and incremental increase in
the early stage of DBS indicates a clinical response [63]. Efforts have been made toward a more
standardized approach to localize SCG in DBS responders [70]. Recently, real-time recording of the
local field potential at the site of electrode implantation coupled with electroencephalogram have
revealed network-wide clinical changes in DBS, which may improve the surgical precision [146].
Tractography-guided localization of electrodes, being more customized and precise, can improve the
response rate [49]. A rechargeable DBS system should also be considered for long-term stimulation to
reduce the need for surgery to replace batteries [17]. Lastly, given the high cost and invasiveness of
DBS, more stringent regulation and evidence from randomized controlled studies are necessary to
justify the benefits in TRD patients [147,148].
9. Conclusions
Major depressive disorder is a debilitating psychiatric condition, which is affected by treatment
resistance. Although safety concerns were raised on the risks of ablative treatment, it paved the way
for deep brain stimulation as an adjustable therapy against depression. This review summarized
the efficacies of deep brain stimulation in the subcallosal cingulate, one of the most extensively
studied targets of stimulation, and in the ventromedial prefrontal cortex, which is the rodent homolog.
Research on DBS initially focused on symptomatic relief. As the decades have progressed, studies have
started to branch out and utilize modern technology to improve targeting of brain regions and
to investigate a broader list of symptoms in patients. This has allowed us to better understand
the impact of DBS on underreported parameters, such as heart rate, skin conductance, and brain
waveforms. Additionally, preclinical research has expanded our understanding of the molecular factors
modulated by stimulation. Besides the local effects, DBS has been shown to modulate distal structures,
which can involve numerous projections to and from the stimulated targets, and can contribute to
the antidepressant effects. This review also described some of the neuroplasticity-dependent and
-independent changes brought about by DBS. Progress in different areas of research has helped lay
the groundwork for the next wave of DBS research investigating more targeted and more effective
applications of DBS for treating MDD. Last but not least, with further customization, more precise
approaches, and more stringent regulation, it is anticipated that deep brain stimulation has great
promise to treat severe, refractory depressive disorders in the near future.
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